Need Help?
Contact Us

Caution: Eluvia is an investigational device. Limited by US law to investigational use only. Not available for sale.

“The 1-year outcome was extraordinary with regard to very low restenosis rate and reintervention rate, which was the lowest ever seen so far for any kind of stent.”

Professor Thomas Zeller, MD
University Heart Center | Freidburg-Bad Krozingen, Germany

Chart showing the MAJESTIC 2-year primary patency rate for the Eluvia Drug-Eluting Vascular Stent System is 83.5%.

MAJESTIC 1- and 2-Year Primary Patency1


Clinically Studied Therapies


Find out how Boston Scientific’s drug-eluting technologies continue to deliver unprecedented clinical outcomes in patients with peripheral artery disease (PAD).

Close up of the Eluvia Drug-Eluting Vascular Stent System

Eluvia Drug-Eluting Vascular Stent System

The Eluvia Drug-Eluting Stent showed unprecedented clinical outcomes—with a 83.5% primary patency at 2 years, the highest reported in comparable SFA clinical trials.

Chart comparing paclitaxel release over time for the Eluvia Drug-Eluting Stent, drug-coated balloons and traditional drug-coated stents.

Drug Tissue Concentrations Over Time 2


Investing in Drug-Eluting Technology


Find out how we’re leveraging nearly 20 years of design and development experience to advance the science of drug-eluting technologies and improve patient lives.

 

Dr. Erwin Blessing discusses data showing that drug-eluting stent technology outperforms bare metal stents.

"We have clear data that the drug-eluting stent technology outperforms a bare metal stent."

Professor Erwin Blessing, MD
SRH Hospital | Karlsbad, Germany

Stay Up to Date

Receive emails about the latest drug-eluting technology news, innovations and events in your area.

Explore DE Resources

Get physician perspectives, clinical data sheets and other resources about drug-eluting innovations.

Top